WallStreetZenWallStreetZen

NASDAQ: CDXS
Codexis Inc Stock

$3.55+0.25 (+7.58%)
Updated Jul 19, 2024
CDXS Price
$3.55
Fair Value Price
-$3.26
Market Cap
$250.48M
52 Week Low
$1.45
52 Week High
$4.91
P/E
-3.82x
P/B
3.16x
P/S
3.28x
PEG
N/A
Dividend Yield
N/A
Revenue
$74.23M
Earnings
-$65.13M
Gross Margin
82.3%
Operating Margin
-87.65%
Profit Margin
-87.7%
Debt to Equity
0.89
Operating Cash Flow
-$51M
Beta
1.54
Next Earnings
Aug 1, 2024
Ex-Dividend
N/A
Next Dividend
N/A

CDXS Overview

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CDXS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CDXS ($3.55) is overvalued by 208.98% relative to our estimate of its Fair Value price of -$3.26 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CDXS ($3.55) is not significantly undervalued (208.98%) relative to our estimate of its Fair Value price of -$3.26 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CDXS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CDXS due diligence checks available for Premium users.

Be the first to know about important CDXS news, forecast changes, insider trades & much more!

CDXS News

Valuation

CDXS fair value

Fair Value of CDXS stock based on Discounted Cash Flow (DCF)
Price
$3.55
Fair Value
-$3.26
Undervalued by
208.98%
CDXS ($3.55) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CDXS ($3.55) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CDXS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CDXS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-3.82x
Industry
-18.27x
Market
29.62x

CDXS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.16x
Industry
6.22x
CDXS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CDXS's financial health

Profit margin

Revenue
$17.1M
Net Income
-$11.5M
Profit Margin
-67.4%
CDXS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CDXS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$149.6M
Liabilities
$70.3M
Debt to equity
0.89
CDXS's short-term assets ($107.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CDXS's short-term assets ($107.95M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CDXS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CDXS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$7.8M
Investing
-$28.6M
Financing
$29.3M
CDXS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CDXS vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CDXS$250.48M+7.58%-3.82x3.16x
FHTX$251.26M-2.32%-2.68x-2.58x
ATAI$247.76M0.00%-7.05x1.11x
ZVRA$253.21M-5.02%-4.48x5.19x
NBTX$254.52M-2.70%-4.65x-128.43x

Codexis Stock FAQ

What is Codexis's quote symbol?

(NASDAQ: CDXS) Codexis trades on the NASDAQ under the ticker symbol CDXS. Codexis stock quotes can also be displayed as NASDAQ: CDXS.

If you're new to stock investing, here's how to buy Codexis stock.

What is the 52 week high and low for Codexis (NASDAQ: CDXS)?

(NASDAQ: CDXS) Codexis's 52-week high was $4.91, and its 52-week low was $1.45. It is currently -27.7% from its 52-week high and 144.83% from its 52-week low.

How much is Codexis stock worth today?

(NASDAQ: CDXS) Codexis currently has 70,557,577 outstanding shares. With Codexis stock trading at $3.55 per share, the total value of Codexis stock (market capitalization) is $250.48M.

Codexis stock was originally listed at a price of $13.26 in Apr 22, 2010. If you had invested in Codexis stock at $13.26, your return over the last 14 years would have been -73.23%, for an annualized return of -8.98% (not including any dividends or dividend reinvestments).

How much is Codexis's stock price per share?

(NASDAQ: CDXS) Codexis stock price per share is $3.55 today (as of Jul 19, 2024).

What is Codexis's Market Cap?

(NASDAQ: CDXS) Codexis's market cap is $250.48M, as of Jul 22, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Codexis's market cap is calculated by multiplying CDXS's current stock price of $3.55 by CDXS's total outstanding shares of 70,557,577.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.